VisiCELL Medical Email Formats

Biotechnology Research • San Diego, California, United States • 11-20 Employees

VisiCELL Medical Email Formats

VisiCELL Medical uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@visicellmedical.com), used 57.1% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@visicellmedical.com	57.1%
{first name}.{last name}	john.doe@visicellmedical.com	42.9%

Key Contacts at VisiCELL Medical

Mya S. Thu

Co-Founder And Ceo

Amilcare Gentili

Co-Founder

Company overview

Headquarters	10918 Technology Pl, San Diego, California 92127, US
Phone number	+18585243299
Website	visicellmedical.com
NAICS	541714
SIC	873
Keywords	In Vivo Imaging, Cell And Gene Therapy, Precision And Personalized Medicine, Cell Labeling And Tracking, Cell Therapy Biodistribution By Mri, Cellular I/O In Solid Tumors And Autoimmune, Clinical Development And Trials, Diagnostic And Biomarker Discovery, Drug Discovery And Preclinical Development, Informatics And Ai Driven Data Analytics, Targeted Cell-Based Therapy, Translational Development
Employees	11-20
Socials

About VisiCELL Medical

VisiCELL Medical Inc., “GPS for Cell Therapy”, is developing in vivo imaging analytics for customers with cell-based therapies in solid tumor cancers, autoimmune diseases and regenerative medicine in the multi-billion dollar cell and gene therapy industry. Visicell’s patented, disruptive technology provides real time imaging insights over time of cell therapies within disease contexts in animals and human patients by standard Magnetic Resonance Imaging (MRI) overcoming the current practical limitations of painful biopsy, single time-point histopathology and noisy PCR, where tissue sample scarcity and inaccessible disease locations are additional obstacles to data collection for informed decision-making. The pharmacokinetic, pharmacodynamic, safety and efficacy information acquired in a longitudinal, repeatable fashion in both preclinical and clinical settings enable faster and more accurate actionable decision-making for improved outcomes. It seamlessly integrates into existing disease response monitoring workflows, such as cancer, neurodegenerative or cardiovascular monitoring. This benefits the cell therapy companies with accelerated product development, shortened time to market and improved outcomes thereby creating competitive advantage and economic value. We are revenue generating, have signed a research collaboration agreement with a large pharma, and are in deep discussion with multiple cell therapy developers for early technology assessment and strategic partnerships for long-term mutual value creation opportunities.